Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.240
-0.100 (-4.27%)
Mar 5, 2026, 4:00 PM EST - Market closed
Moleculin Biotech Stock Forecast
MBRX's stock price has decreased by -91.56% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Moleculin Biotech stock have an average target of 105.5, with a low estimate of 22 and a high estimate of 200. The average target predicts an increase of 4,609.82% from the current stock price of 2.24.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 11, 2025.
Analyst Ratings
The average analyst rating for Moleculin Biotech stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $4 → $22 | Strong Buy | Maintains | $4 → $22 | +882.14% | Dec 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +4,364.29% | Sep 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +4,364.29% | Aug 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +4,364.29% | Jun 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $100 | Strong Buy | Initiates | $100 | +4,364.29% | Jun 9, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-37.08
from -158.02
EPS Next Year
-8.08
from -37.08
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -33.01 | -5.07 | ||
| Avg | -37.08 | -8.08 | ||
| Low | -38.05 | -9.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.